<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03866200</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-0573</org_study_id>
    <nct_id>NCT03866200</nct_id>
  </id_info>
  <brief_title>Resveratrol Trial for Relief of Pain in Pseudoachondroplasia</brief_title>
  <official_title>Resveratrol Trial for Relief of Pain in Pseudoachondroplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if self-administered oral resveratrol can dampen
      joint pain for individuals with pseudoachondroplasia compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in pain as assessed numeric pain rating scale</measure>
    <time_frame>baseline, 30 days</time_frame>
    <description>total score 0-10 with higher scores indicating greater pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in pain as assessed numeric pain rating scale</measure>
    <time_frame>baseline, 60 days</time_frame>
    <description>total score 0-10 with higher scores indicating greater pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in pain as assessed numeric pain rating scale</measure>
    <time_frame>baseline, 90 days</time_frame>
    <description>total score 0-10 with higher scores indicating greater pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life score (HRQoL) assessed by 36-item short form health survey short form-36 (SF-36)</measure>
    <time_frame>baseline, 30 days</time_frame>
    <description>total score 0-100 with higher scores indicating better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life score (HRQoL) assessed by 36-item short form health survey short form-36 (SF-36)</measure>
    <time_frame>baseline, 60 days</time_frame>
    <description>total score 0-100 with higher scores indicating better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life score (HRQoL) assessed by 36-item short form health survey short form-36 (SF-36)</measure>
    <time_frame>baseline, 90 days</time_frame>
    <description>total score 0-100 with higher scores indicating better outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pseudoachondroplasia</condition>
  <arm_group>
    <arm_group_label>resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>resveratrol</intervention_name>
    <description>125 mg/day or 5 ml once per day for 90 days</description>
    <arm_group_label>resveratrol</arm_group_label>
    <other_name>resverages super berry tonic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 ml once per day for 90 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of pseudoachondroplasia is based on clinical assessment either in person
             or by photographic review by skeletal dysplasia specialist (JTH),

          -  Healthy beyond pseudoachondroplasia associated complications,

        Exclusion Criteria:

          -  Current use of resveratrol

          -  Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine
             and triazolam.

          -  Other non-pseudoachondroplasia related health conditions, e.g. cancers.

          -  Pregnancy or breastfeeding. Women must use adequate contraception during the study.

          -  Participation in another clinical study and/or using investigational agents.

          -  Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.

          -  Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine,
             Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir,
             Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine,
             Fosphenytoin, Phenytoin or Warfarin.

          -  Baseline level of pain of 2 or higher on 10 point scale.

          -  Platelet count below 50,000 per ul on baseline complete blood count (CBC).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Posey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Posey, PhD</last_name>
    <phone>7135005786</phone>
    <email>karen.posey@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Posey</last_name>
      <phone>713-500-5786</phone>
      <email>karen.posey@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 5, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Karen Posey</investigator_full_name>
    <investigator_title>Assoc. Professor</investigator_title>
  </responsible_party>
  <keyword>resveratrol</keyword>
  <keyword>joint pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achondroplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

